Sipuleucel-T, also known as Provenge, is not recommended within its marketing authorization for treating adults who have asymptomatic or minimally symptomatic Metastatic non–visceral hormone–relapsed prostate cancer for which chemotherapy is not yet clinically indicated. The topic was one of ours, with Emma Simpson, Sarah Davis, Praveen Thokala, Penny Breeze and Ruth Wong from HEDS doing the work.
Whilst the HEDS Blog has given an overview previously, something interesting was missed out. Adjustment for treatment switching was problematic as both the IPCW and IPE had problems…..there was not the necessary data on covariates to apply the IPCW, whilst the assumptions of the IPE were not consistent with the model structure (p79-80 of the ERG report). More methods research on switching is required……
